301258 Suzhou Fushilai Pharmaceutical
- 26.00
- -1.50-5.45%
Suzhou Fushilai Pharmaceutical News
Fujilai (301258.SZ): Cumulatively repurchased 89,000 shares.
Fujilai (301258.SZ) announced that as of May 31, 2024, the company has repurchased a cumulative total of 89,400 shares of the company through the share buyback special securities account in the form of centralized bidding trading, accounting for 0.0975% of the company's current total share capital. The highest fill price is 25.28 yuan/share, and the lowest fill price is 21.68 yuan/share, using a total amount of 2,007,640.00 yuan (excluding transaction fees).
Fujilai (301258.SZ) plans to distribute 6.005202 yuan per 10 shares on June 12th after ex-rights and ex-dividends.
Fujilai (301258.SZ) announced that the company's 2023 annual equity distribution plan is: to distribute 10 shares to all shareholders ...
Suzhou Fushilai Pharmaceutical Co., Ltd. (SZSE:301258) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Most readers would already be aware that Suzhou Fushilai Pharmaceutical's (SZSE:301258) stock increased significantly by 38% over the past month. However, we decided to pay attention to the company'
Fujilai (301258.SZ): No plans for cellular immunotherapy
Gelonghui, May 10 | Fujilai (301258.SZ) said on the investor interactive platform that the company has no plans for cellular immunotherapy yet.
Synthetic organisms are now differentiated! Big bulls have advanced to the 5th straight board, and policy expectations haven't been met yet?
There will be major policies in the future
Fujilai (301258.SZ): R-lipoic acid produced by enzymatic method has been mass-produced and sold abroad
Gelonghui, May 6 | Fujilai (301258.SZ) said on the investor interactive platform that R-lipoic acid produced by the company's enzymatic method has been mass-produced and is currently still in the marketing stage. Whether it can completely replace the original process depends on various factors such as market demand and customer acceptance.
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Fujilai (301258.SZ): Net profit of 5.786,800 yuan in the first quarter decreased by 88.79% year on year
Gelonghui, April 22 | Fujilai (301258.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 96.2913 million yuan, down 38.47% year on year; net profit attributable to shareholders of listed companies was 5.7868 million yuan, down 88.79% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 3.1951 million yuan, down 92.87% year on year; basic earnings per share were 0.0631 yuan.
Fujilai (301258.SZ): Currently not involved in the production of anti-nuclear radiation products
Gelonghui, April 12 | Fujilai (301258.SZ) said on the investor interactive platform that the company is currently not involved in the production of anti-nuclear radiation products. In the pharmaceutical field, lipoic acid is used to treat various diseases such as diabetic peripheral neuropathy and neurological complications; in the field of health products, it has the effect of removing free radicals from the body and preventing lipid peroxidation, and can delay aging, beauty, and activate cells, and is used in oral nutritional products.
Fujilai (301258.SZ): Supervisor Qian Yi plans to reduce holdings by no more than 562,000 shares
Gelonghui, April 2 | Fujilai (301258.SZ) announced that Supervisor Qian Yi plans to reduce her holdings of no more than 56,200 shares through centralized bidding, accounting for 0.0613% of the company's total share capital after excluding the repurchase of shares, within 3 months of 15 trading days from the date of the announcement of the capital reduction plan.
Fujilai (301258.SZ): Total number of shareholders as of March 29, 2024 was 1,1811
Gelonghui, April 2 | Fujilai (301258.SZ) said on the investor interactive platform that the total number of shareholders as of March 29, 2024 was 11,811.
Fujilai (301258.SZ): Total number of shareholders as of March 8, 2024 was 11,370
Gelonghui March 11 | Fujilai (301258.SZ) said on the investor interactive platform that the total number of shareholders as of March 8, 2024 was 11,370.
Fujilai (301258.SZ): Initial repurchase of 10,000 shares involving 252,400 yuan
Gelonghui (301258.SZ) announced on March 1, 2024, that on February 29, 2024, the number of shares of the company was repurchased for the first time through a special stock repurchase securities account with a centralized bidding transaction of 10,000 shares, accounting for 0.0109% of the company's current total share capital. The highest transaction price was 25.28 yuan/share, the minimum transaction price was 25.20 yuan/share, and the total capital used was 252,400 yuan (excluding transaction fees).
Fujilai (301258.SZ) has been re-certified as a high-tech enterprise
Gelonghui, Feb. 20 | Fujilai (301258.SZ) announced that the company recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. Certificate number: [GR202332000244], date of issue: November 6, 2023, validity period: three years.
Fujilai (301258.SZ) performance report: 2023 net profit of 113 million yuan fell 36.38% year on year
Gelonghui, Feb. 19 | Fujilai (301258.SZ) announced its 2023 annual results report. According to preliminary accounting, in 2023, the company achieved total operating revenue of 489 million yuan, down 13.89% from the same period of the previous year; operating profit of 135 million yuan, down 34.42% from the same period of the previous year; total profit of 129 million yuan, down 36.07% from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss 8915,500 yuan, compared to
Fujilai (301258.SZ): Plans to spend 20 million yuan to 40 million yuan to buy back the company's shares
Glonghui, Feb. 6 | Fujilai (301258.SZ) announced that the company plans to use its own funds to repurchase RMB common stock (A shares) shares issued by the company through centralized bidding transactions. The total capital for the repurchase of shares is not less than RMB 20 million (including capital) and not more than RMB 40 million (including capital). The total amount of repurchase capital is based on the total amount of capital actually used. The repurchase price of shares shall not exceed RMB 40.00 per share (inclusive). The implementation period for the share repurchase is within 12 months from the date the board of directors of the company reviewed and approved the repurchase plan. The purpose of repurchasing shares: Will
Are Suzhou Fushilai Pharmaceutical Co., Ltd.'s (SZSE:301258) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Suzhou Fushilai Pharmaceutical (SZSE:301258) has had a rough three months with its share price down 32%. But if you pay close attention, you might find that its key financial indicators look quite d
Fujilai (301258.SZ): Total number of shareholders as of January 31, 2024 was 12,146
On February 2, GLONGHUI (301258.SZ) said on the investor interactive platform that the total number of shareholders as of January 31, 2024 was 12,146.
Fujilai (301258.SZ) currently has no business cooperation with Minovar
GLONGHUI January 29丨Fujilai (301258.SZ) said on the investor interactive platform that the company currently has no business cooperation with Minovar.
Fujilai (301258.SZ): There is currently no smoking cessation drug program
Gelonghui January 17 | Fujilai (301258.SZ) said on the investor interactive platform that the company currently has no smoking cessation drug programs.
Analysis
Price Target
No Data
